US20110223164A1 - Binding domain-immunoglobulin fusion proteins - Google Patents

Binding domain-immunoglobulin fusion proteins Download PDF

Info

Publication number
US20110223164A1
US20110223164A1 US13/039,097 US201113039097A US2011223164A1 US 20110223164 A1 US20110223164 A1 US 20110223164A1 US 201113039097 A US201113039097 A US 201113039097A US 2011223164 A1 US2011223164 A1 US 2011223164A1
Authority
US
United States
Prior art keywords
seq id
cells
immunoglobulin
polypeptide
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/039,097
Inventor
Jeffrey A. Ledbetter
Martha S. Hayden-Ledbetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Product Development Seattle LLC
Original Assignee
Emergent Product Development Seattle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US36735801P priority Critical
Priority to US10/053,530 priority patent/US20030133939A1/en
Priority to US38569102P priority
Priority to US10/207,655 priority patent/US7754208B2/en
Priority to US12/724,333 priority patent/US20100203052A1/en
Application filed by Emergent Product Development Seattle LLC filed Critical Emergent Product Development Seattle LLC
Priority to US13/039,097 priority patent/US20110223164A1/en
Publication of US20110223164A1 publication Critical patent/US20110223164A1/en
Assigned to GENECRAFT, INC. reassignment GENECRAFT, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAYDEN-LEDBETTER, MARTHA, LEDBETTER, JEFFREY A., THOMPSON, PETER A.
Assigned to TRUBION PHARMACEUTICALS, INC. reassignment TRUBION PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GENECRAFT, INC.
Assigned to EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC reassignment EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: TRUBION PHARMACEUTICALS, INC.
Application status is Abandoned legal-status Critical

Links